BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38537878)

  • 1. Expanding the horizon of transient CAR T therapeutics using virus-free technology.
    Enriquez-Rodriguez L; Attia N; Gallego I; Mashal M; Maldonado I; Puras G; Pedraz JL
    Biotechnol Adv; 2024; 72():108350. PubMed ID: 38537878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T-Cell Production Using Nonviral Approaches.
    Lukjanov V; Koutná I; Šimara P
    J Immunol Res; 2021; 2021():6644685. PubMed ID: 33855089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better by design: What to expect from novel CAR-engineered cell therapies?
    Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
    Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-T Cell Therapy: Challenges and Optimization.
    Luo M; Zhang H; Zhu L; Xu Q; Gao Q
    Crit Rev Immunol; 2021; 41(1):77-87. PubMed ID: 33822526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Khan AN; Asija S; Pendhari J; Purwar R
    Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomaterials for chimeric antigen receptor T cell engineering.
    Niu H; Zhao P; Sun W
    Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
    Brookens SK; Posey AD
    Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
    Liu J; Zhou G; Zhang L; Zhao Q
    Front Immunol; 2019; 10():456. PubMed ID: 30941126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
    Sun W; Jiang Z; Jiang W; Yang R
    Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuning the performance of CAR T cell immunotherapies.
    Richardson NH; Luttrell JB; Bryant JS; Chamberlain D; Khawaja S; Neeli I; Radic M
    BMC Biotechnol; 2019 Nov; 19(1):84. PubMed ID: 31783836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
    Ruppel KE; Fricke S; Köhl U; Schmiedel D
    Front Immunol; 2022; 13():822298. PubMed ID: 35371071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights.
    Pu Z; Wang TB; Mou L
    Front Immunol; 2023; 14():1310285. PubMed ID: 38090577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymer- and lipid-based gene delivery technology for CAR T cell therapy.
    Pinto IS; Cordeiro RA; Faneca H
    J Control Release; 2023 Jan; 353():196-215. PubMed ID: 36423871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.